Department of Oncology, Institute of Biomedicine and Surgery, University of Linköping, Linköping, Sweden.
Oncol Rep. 2012 Feb;27(2):376-82. doi: 10.3892/or.2011.1521. Epub 2011 Oct 24.
The present study investigated the expression of the novel gene hBiot2 in colorectal cancer (CRC) and its relationships with clinicopathological variables in CRC patients. The expression of hBiot2 in 163 primary CRCs together with the corresponding normal mucosa, 36 liver metastases and 5 colon cancer cell lines was examined using real-time PCR. In situ hybridization (ISH) was performed to evaluate the localization of hBiot2 expression in CRC and normal mucosa. hBiot2 expression at the RNA level was localized in the nucleus of tumor cells and normal epithelial cells. The mean expression of hBiot2 in the CRCs (243.571±564.569) was higher compared to the normal mucosa (107.252±413.635, P<0.0001) and liver metastasis samples (42.002±40.809, P=0.0002). hBiot2 expression was increased from stages I+II to III (P=0.047), and no difference in the expression was found in stages III and IV (P=0.452). A high value of hBiot2 was associated with a poorer prognosis compared with a low value independently of gender, age, tumor site, stage and differentiation (P=0.007, RR 7.519, 95% CI 1.729-32.704). Liver metastasis, smaller tumors, non-local recurrence and primary liver surgery alone were associated with a higher value of hBiot2 compared to larger tumors, local recurrence and repeated liver surgery (P=0.003, 0.044 and 0.026, respectively). An inverse relationship was found between hBiot2 expression and the metastatic potential of the colon cancer cell lines. Thus, increased expression of hBiot2 may be an early and interim event in the development of CRC. A higher expression of hBiot2 in primary CRC patients independently indicates a poorer prognosis.
本研究调查了新型基因 hBiot2 在结直肠癌（CRC）中的表达及其与 CRC 患者临床病理变量的关系。使用实时 PCR 检测 163 例原发性 CRC 及其相应的正常黏膜、36 例肝转移和 5 株结肠癌细胞系中 hBiot2 的表达。通过原位杂交（ISH）评估 hBiot2 表达在 CRC 和正常黏膜中的定位。hBiot2 在肿瘤细胞和正常上皮细胞的核内表达。CRC 中 hBiot2 的平均表达（243.571±564.569）高于正常黏膜（107.252±413.635，P<0.0001）和肝转移样本（42.002±40.809，P=0.0002）。hBiot2 的表达从 I+II 期增加到 III 期（P=0.047），但 III 期和 IV 期之间的表达无差异（P=0.452）。与低值相比，高值 hBiot2 与预后不良独立相关，与性别、年龄、肿瘤部位、分期和分化无关（P=0.007，RR 7.519，95%CI 1.729-32.704）。与较大肿瘤、局部复发和重复肝切除术相比，肝转移、较小肿瘤、非局部复发和单纯肝切除术与更高的 hBiot2 值相关（P=0.003、0.044 和 0.026）。hBiot2 表达与结肠癌细胞系转移潜能呈负相关。因此，hBiot2 的表达增加可能是 CRC 发展的早期和中期事件。hBiot2 在原发性 CRC 患者中的高表达独立预示预后不良。
